Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity

Antonia Stubenvoll; Maria Schmidt; Johanna Moeller; Max Alexander Lingner Chango; Carolyn Schultz; Olga Antoniadou; Henry Loeffler-Wirth; Stephan Bernhart; Florian Große; Beatrice Thier; Annette Paschen; Ulf Anderegg; Jan C. Simon; Mirjana Ziemer; Clara T. Schoeder; Hans Binder; Manfred Kunz

doi:10.1002/cac2.12651

Cancer Communications ›› 2025, Vol. 45 ›› Issue (4) : 460 -464. DOI: 10.1002/cac2.12651

LETTER TO THE JOURNAL

Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity

Author information +

History +

PDF

Cite this article

Download citation ▾

Antonia Stubenvoll, Maria Schmidt, Johanna Moeller, Max Alexander Lingner Chango, Carolyn Schultz, Olga Antoniadou, Henry Loeffler-Wirth, Stephan Bernhart, Florian Große, Beatrice Thier, Annette Paschen, Ulf Anderegg, Jan C. Simon, Mirjana Ziemer, Clara T. Schoeder, Hans Binder, Manfred Kunz. Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity. Cancer Communications, 2025, 45(4): 460-464 DOI:10.1002/cac2.12651

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, et al. The treatment of advanced melanoma: Current approaches and new challenges. Crit Rev Oncol Hematol. 2024; 196: 104276.

[2]	Reynolds G, Vegh P, Fletcher J, Poyner EFM, Stephenson E, Goh I, et al. Developmental cell programs are co-opted in inflammatory skin disease. Science 2021; 371(6527): eaba6500.

[3]	Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018; 33: 890–904.e5.

[4]	Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ. Generalizing RNA velocity to transient cell states through dynamical modeling. Nat Biotechnol. 2020; 38: 1408–1414.

[5]	Wu QW. Serpine2, a potential novel target for combating melanoma metastasis. Am J Transl Res. 2016; 8: 1985–1997.

[6]	Jiang T, Zhou W, Chang Z, Zou H, Bai J, Sun Q, et al. ImmReg: the regulon atlas of immune-related pathways across cancer types. Nucleic Acids Res. 2021; 49: 12106–12118.

[7]	Igarashi K, Nishizawa H, Saiki Y, Matsumoto M. The transcription factor BACH1 at the crossroads of cancer biology: From epithelial-mesenchymal transition to ferroptosis. J Biol Chem. 2021; 297: 101032.

[8]	Frangieh CJ, Melms JC, Thakore PI, Geiger-Schuller KR, Ho P, Luoma AM, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021; 53: 332–341.

[9]	Su C, Mo J, Dong S, Liao Z, Zhang B, Zhu P. Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets. Cell Commun Signal. 2024; 22: 71.

[10]	Pan B, Wang Z, Zhang X, Shen S, Ke X, Qiu J, et al. Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8+ T cells in hepatocellular carcinoma. Commun Biol. 2023; 6: 123.